Table 3.
Correlation between levels of lncRNA-based Index I and clinicopathological characteristics of patients with GC from the discovery, training and validation phases.
| Variables | lncRNA-based Index I | P value | |
|---|---|---|---|
| High levels (N, %) | Low levels (N, %) | ||
| Age, y | 0.393 | ||
| ≥ 55 | 37 (58.7) | 41 (66.1) | |
| ˂ 55 | 26 (41.3) | 21 (33.9) | |
| Gender | 0.091 | ||
| Male | 51 (81.0) | 42 (67.7) | |
| Female | 12 (29.0) | 20 (32.3) | |
| Size | 0.036 | ||
| ≥ 5 cm | 45 (71.4) | 33 (53.2) | |
| ˂ 5 cm | 18 (28.6) | 29 (46.8) | |
| Differentiation | 0.290 | ||
| Well/moderate | 25 (39.7) | 19 (30.6) | |
| Poor/undifferentiated | 38 (61.3) | 43 (69.4) | |
| Depth of invasion | 0.025 | ||
| T1/2 | 26 (41.3) | 38 (61.3) | |
| T3/4 | 37 (58.7) | 24 (38.7) | |
| Lymphatic metastasis | 0.012 | ||
| Positive | 48 (76.2) | 34 (54.8) | |
| Negative | 15 (23.8) | 28 (45.2) | |
| Distant metastasis | 1.000# | ||
| Positive | 2 (3.2) | 1 (1.6) | |
| Negative | 61 (96.8) | 61 (98.4) | |
| pTNM stage | 0.003 | ||
| I/II | 22 (34.9) | 38 (61.3) | |
| III/IV | 41 (65.1) | 24 (38.7) | |
# Fisher's exact test.